CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients.
CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients.
复制标题
CD24是非小细胞肺癌患者中生存的独立预后标记。
DOI：
10.1038/sj.bjc.6600702
复制
发表时间：
2003-01-27
影响因子：
8.8
通讯作者：
Petersen, I
中科院分区：
文献类型：
--
作者：
Kristiansen, G;Schluns, K;Yongwei, Y;Denkert, C;Dietel, M;Petersen, I
最初被鉴定为B细胞标志物，同时在多种人类恶性肿瘤中观察到细胞表面分子CD 24的表达。它似乎作为P-选择素的配体发挥作用，P-选择素是一种存在于活化血小板和内皮细胞中的粘附分子。我们的目的是确定我们收集的非小细胞肺癌（NSCLC）中CD 24的表达率，并阐明其与包括患者生存率在内的临床病理参数的相关性。使用单克隆CD 24抗体（克隆24 C 02）和标准检测系统（LSAB，DAKO）在NSCLC组织微阵列（TMA）上对共计89例NSCLC进行了免疫化学分析。对染色进行半定量评分（0，1+，2+，3+），并分为高（2+，3+）和低（0，1+）水平表达进行统计分析。在45%的病例中观察到高水平的CD 24表达，优先为腺癌。肿瘤具有高CD 24表达的患者的中位生存时间显著较短，为23个月比38个月（P=0.033，对数秩检验）。同样，在单变量生存分析中，肿瘤分级、淋巴结状态和临床分期是重要的预后指标。重要的是，在基于考克斯回归的多变量分析中，CD 24表达（P=0.025）与肿瘤分期（P=0.006）和分级（P=0.011）一起被证明是独立的预后参数。我们假设，具有强CD 24阳性肿瘤的NSCLC患者的生存率降低与血行转移形成的倾向增强有关，这可能是P-选择素介导的。
Originally identified as a B-cell marker, expression of the cell surface molecule CD24 has meanwhile been observed in a variety of human malignancies. It appears to function as a ligand of P-Selectin, an adhesion molecule that is present in activated platelets and endothelial cells. We aimed to determine the rate of CD24 expression in our nonsmall cell lung cancer (NSCLC) collection and to clarify its correlation with clinicopathological parameters including patients' survival. A total of 89 NSCLC were analysed immunohistochemically using a monoclonal CD24 antibody (clone 24C02) and a standard detection system (LSAB, DAKO) on NSCLC tissue microarrays (TMA). The staining was semiquantitatively scored (0, 1+, 2+, 3+) and grouped into high (2+, 3+)- and low (0, 1+)-level expression for statistical analysis. A high level of CD24 expression was observed in 45% of the cases, preferentially adenocarcinomas. Patients whose tumours had a high CD24 expression showed a significantly shorter median survival time of 23 months vs 38 months (P=0.033, log-rank test). Similarly tumour, grading, nodal status and clinical stage were significant prognostic markers in univariate survival analysis. Importantly, in the Cox regression-based multivariate analysis, CD24 expression (P=0.025) together with tumour stage (P=0.006) and grade (P=0.011) proved to be independent prognostic parameters. We hypothesise that the decreased survival of NSCLC patients with strongly CD24-positive tumours is related to an enhanced propensity of haematogenous metastasis formation, which might be P-Selectin mediated.